RecruitingNCT05432024

Evaluation of Ablation Lesions Using Cardiovascular Magnetic Resonance Imaging


Sponsor

R&D Cardiologie

Enrollment

60 participants

Start Date

Mar 8, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Ineffective ablation lesions can cause arrhythmia recurrence after catheter ablation for cardiac arrhythmia. Ablation lesions can be created with various ablation energy modalities. This study uses cardiovascular magnetic resonance imaging to evaluate the ablation lesion characteristics of radiofrequency ablation, ultra-low temperature cryo ablation, and pulsed field ablation. The ablation lesion characteristics of different energy characteristics will be compared. Additionally, arrhythmia recurrence and quality of life will be evaluated for the different energy modalities.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Adult patients (age ≥18 years old)
  • Paroxysmal or persistent atrial fibrillation, meeting criteria of the 2020 European Society of Cardiology Guidelines for diagnosis and management of atrial fibrillation
  • Patients scheduled to undergo catheter ablation for cardiac arrhythmia using one of the following techniques: Radiofrequency ablation (High power, short duration), Ultra-low temperature cryo ablation, or Pulsed field ablation

Exclusion Criteria4

  • Known (or suspected) allergic reaction to gadolinium
  • Contraindications for MRI (such as claustrophobia, certain implants, devices, high body mass index).
  • Pregnancy or breastfeeding
  • Prior intervention in the left atrium (ablation or surgery)

Interventions

DEVICECatheter ablation

An ablation catheter is introduced in the heart. Ablation is performed by applying ablation energy to the target tissue. The aim of ablation is to create an ablation lesion that does not conduct the electrical signals that induce or sustain the cardiac arrhythmia.


Locations(1)

St. Antonius Hospital

Nieuwegein, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05432024


Related Trials